XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means the FDA has not approved the drug for your type of cancer.

Cabozantanib (XL184) is a new drug that is being developed to treat cancer. The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in multiple myeloma growth, its ability to spread, and its ability to form new blood vessels. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to slow or stop disease growth to bones and prevent cancer growth.

In this research study, we are looking to see how effective cabozantanib is in slowing or stopping disease growth to the bones as well as preventing your cancer from worsening. We are also looking for the highest dose of cabozantinib that can be given safely to patients who have multiple myeloma with bone disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital

Criteria

Inclusion Criteria:

• Relapsed/Refractory Multiple Myeloma

• Skeletal lesions suggestive of bone involvement

• Must have received at least 2 lines of prior systemic therapy for the treatment of multiple myeloma

• Must have received prior treatment with a proteasome inhibitor

• Agree to use medically accepted barrier method of contraception

• Not a candidate for ASCT, has declined the option or has relapsed after prior ASCT

Exclusion Criteria:

• Pregnant or breastfeeding

• Has received radiotherapy to thoracic cavity or GI tract (within 3 months of first dose of study drug), bone or brain metastasis (within 14 days of first dose) or any other site (within 28 days)

• Has received any other investigational agent within 28 days

• Primary brain tumor

• Uncontrolled, significant intercurrent or recent illness

• Cardiovascular disorder(s)

• Gastrointestinal disorder(s)